Limits...
The Serine Protease Inhibitor, 4-(2-aminoethyl) Benzene Sulfonyl Fluoride Hydrochloride, Reduces Allergic Inflammation in a House Dust Mite Allergic Rhinitis Mouse Model.

Kim BY, Park HR, Shin JH, Kim SW, Cho JH, Park YJ, Kim SW - Allergy Asthma Immunol Res (2014)

Bottom Line: Additionally, the percentage of CD4(+)CD25(+)Foxp3(+) T cells, IL-10 levels, and Foxp3 mRNA levels increased in the S and C groups compared with those in the Derf group (P<0.05).AEBSF treatment decreased the proteolytic activity in the S and C groups (P<0.05).Prophylactic and therapeutic treatment with AEBSF significantly reduces allergic airway inflammation and can induce regulatory T cells in a murine model of AR.

View Article: PubMed Central - PubMed

Affiliation: Department of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea, College of Medicine, Seoul, Korea.

ABSTRACT

Purpose: Serine protease inhibitors are involved in immune development, anti-inflammatory mechanisms, and tissue repair. In the present study, the serine protease inhibitor 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride (AEBSF) was evaluated for its prophylactic and therapeutic applications in a mouse model of allergic rhinitis (AR).

Methods: BALB/c mice were divided into 5 groups: contol (CON), Dermatophagoides farinae (Derf), AR mice treated with AEBSF before sensitization (S), AR mice treated with AEBSF after challenge (C), and steroid groups. Derf was used as an allergen. AEBSF was administered before S or after C. Allergic symptom scores, eosinophil counts, proteolytic activity, interferon-γ, interleukin (IL)-10 levels and serum Derf-specific IgE levels were measured. T-bet, GATA-3, Foxp3, IL-13, and transforming growth factor (TGF)-β mRNA levels were determined using real-time polymerase chain reaction. CD4(+)CD25(+)Foxp3(+) T cells were assessed using flow cytometry.

Results: Symptom scores, serum Derf-specific IgE levels, GATA-3 mRNA levels, IL-13 mRNA levels, and tissue eosinophil counts decreased in both the S and C groups (P<0.05). Additionally, the percentage of CD4(+)CD25(+)Foxp3(+) T cells, IL-10 levels, and Foxp3 mRNA levels increased in the S and C groups compared with those in the Derf group (P<0.05). AEBSF treatment decreased the proteolytic activity in the S and C groups (P<0.05).

Conclusions: Prophylactic and therapeutic treatment with AEBSF significantly reduces allergic airway inflammation and can induce regulatory T cells in a murine model of AR.

No MeSH data available.


Related in: MedlinePlus

Data are expressed as days. Schematic representation of the experimental allergic rhinitis model and treatment protocol. Mice in the steroid group were treated intranasally with 20 µg of ciclesonide on days 26-28. AEBSF, 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride; S, AEBSF before sensitization; C, AEBSF after challenge; Derf, Dermatophagoides farinae; IP, intraperitoneal administration; IN, intranasal administration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214977&req=5

Figure 1: Data are expressed as days. Schematic representation of the experimental allergic rhinitis model and treatment protocol. Mice in the steroid group were treated intranasally with 20 µg of ciclesonide on days 26-28. AEBSF, 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride; S, AEBSF before sensitization; C, AEBSF after challenge; Derf, Dermatophagoides farinae; IP, intraperitoneal administration; IN, intranasal administration.

Mentions: Forty mice were randomized into 5 groups: CON (control, n=8), Derf (AR mice, n=8), S (AR mice treated with AEBSF before sensitization, n=8), C (AR mice treated with AEBSF after challenge, n=8), and steroid (AR mice treated with steroid before challenge, n=8). Allergen sensitization and challenge for development of the AR murine model are summarized in Fig. 1. Briefly, on days 2, 9, and 16, all mice were immunized by intraperitoneal injection of 100 µg Derf and 1-mg aluminum hydroxide (Sigma Aldrich). Mice in the S group were treated intranasally with 10 µg AEBSF on days 0-2. One week after sensitization, all mice were challenged intranasally with 20 µg Derf for 6 consecutive days. Mice in the C group were treated intranasally with 10 µg AEBSF on days 26-28. Mice in the steroid group were treated intranasally with 20 µg of ciclesonide on days 26-28. The control group received PBS intranasally instead of Derf.9


The Serine Protease Inhibitor, 4-(2-aminoethyl) Benzene Sulfonyl Fluoride Hydrochloride, Reduces Allergic Inflammation in a House Dust Mite Allergic Rhinitis Mouse Model.

Kim BY, Park HR, Shin JH, Kim SW, Cho JH, Park YJ, Kim SW - Allergy Asthma Immunol Res (2014)

Data are expressed as days. Schematic representation of the experimental allergic rhinitis model and treatment protocol. Mice in the steroid group were treated intranasally with 20 µg of ciclesonide on days 26-28. AEBSF, 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride; S, AEBSF before sensitization; C, AEBSF after challenge; Derf, Dermatophagoides farinae; IP, intraperitoneal administration; IN, intranasal administration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214977&req=5

Figure 1: Data are expressed as days. Schematic representation of the experimental allergic rhinitis model and treatment protocol. Mice in the steroid group were treated intranasally with 20 µg of ciclesonide on days 26-28. AEBSF, 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride; S, AEBSF before sensitization; C, AEBSF after challenge; Derf, Dermatophagoides farinae; IP, intraperitoneal administration; IN, intranasal administration.
Mentions: Forty mice were randomized into 5 groups: CON (control, n=8), Derf (AR mice, n=8), S (AR mice treated with AEBSF before sensitization, n=8), C (AR mice treated with AEBSF after challenge, n=8), and steroid (AR mice treated with steroid before challenge, n=8). Allergen sensitization and challenge for development of the AR murine model are summarized in Fig. 1. Briefly, on days 2, 9, and 16, all mice were immunized by intraperitoneal injection of 100 µg Derf and 1-mg aluminum hydroxide (Sigma Aldrich). Mice in the S group were treated intranasally with 10 µg AEBSF on days 0-2. One week after sensitization, all mice were challenged intranasally with 20 µg Derf for 6 consecutive days. Mice in the C group were treated intranasally with 10 µg AEBSF on days 26-28. Mice in the steroid group were treated intranasally with 20 µg of ciclesonide on days 26-28. The control group received PBS intranasally instead of Derf.9

Bottom Line: Additionally, the percentage of CD4(+)CD25(+)Foxp3(+) T cells, IL-10 levels, and Foxp3 mRNA levels increased in the S and C groups compared with those in the Derf group (P<0.05).AEBSF treatment decreased the proteolytic activity in the S and C groups (P<0.05).Prophylactic and therapeutic treatment with AEBSF significantly reduces allergic airway inflammation and can induce regulatory T cells in a murine model of AR.

View Article: PubMed Central - PubMed

Affiliation: Department of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea, College of Medicine, Seoul, Korea.

ABSTRACT

Purpose: Serine protease inhibitors are involved in immune development, anti-inflammatory mechanisms, and tissue repair. In the present study, the serine protease inhibitor 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride (AEBSF) was evaluated for its prophylactic and therapeutic applications in a mouse model of allergic rhinitis (AR).

Methods: BALB/c mice were divided into 5 groups: contol (CON), Dermatophagoides farinae (Derf), AR mice treated with AEBSF before sensitization (S), AR mice treated with AEBSF after challenge (C), and steroid groups. Derf was used as an allergen. AEBSF was administered before S or after C. Allergic symptom scores, eosinophil counts, proteolytic activity, interferon-γ, interleukin (IL)-10 levels and serum Derf-specific IgE levels were measured. T-bet, GATA-3, Foxp3, IL-13, and transforming growth factor (TGF)-β mRNA levels were determined using real-time polymerase chain reaction. CD4(+)CD25(+)Foxp3(+) T cells were assessed using flow cytometry.

Results: Symptom scores, serum Derf-specific IgE levels, GATA-3 mRNA levels, IL-13 mRNA levels, and tissue eosinophil counts decreased in both the S and C groups (P<0.05). Additionally, the percentage of CD4(+)CD25(+)Foxp3(+) T cells, IL-10 levels, and Foxp3 mRNA levels increased in the S and C groups compared with those in the Derf group (P<0.05). AEBSF treatment decreased the proteolytic activity in the S and C groups (P<0.05).

Conclusions: Prophylactic and therapeutic treatment with AEBSF significantly reduces allergic airway inflammation and can induce regulatory T cells in a murine model of AR.

No MeSH data available.


Related in: MedlinePlus